Reduction of vulvovaginal symptoms in postmenopausal women similar in all three groups.
Similar reductions were seen for most bothersome symptom severity for all treatment groups over 12 weeks (estradiol, −1.4; moisturizer, −1.2; and placebo, −1.3).
Chronic pain patients being treated with certain opioid and non-opioid medications had significantly lower serum concentrations of free testosterone and free estradiol.
Clinical Pain Advisor Articles
- Reviewing the Efficacy, Safety, and Tolerability of Cannabis-Based Medicines for Chronic Neuropathic Pain
- Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis
- Tackling the Chronic Pain and Opioid Use Disorder Crises Through Public-Private Partnerships
- How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics
- Pain Tolerance in Buprenorphine Maintenance Treatment
- Radiofrequency Ablation for Chronic Hip Pain: Reviewing the Evidence
- Opioid Use Disorder Treatment: Evidence-Based Guideline
- Betel Quid Addiction and Implications for Substance Use Disorder
- Low Back Pain: Contributing Factors, Prophylactic Strategies, and Effective Treatments
- Peripherally Acting Opioid and Cannabinoid May Be Effective for Neuropathic Pain
- Transcranial Magnetic Stimulation May Prevent Migraine in Adolescents
- Widespread Impact of Reducing Opioids, Adding IV Acetaminophen for Postsurgical Pain Management
- GI Safety Compared for NSAIDs in Patients With Arthritis
- Opioid Prescribing Trends in Patients With, Without Cancer
- DOJ Rescinds Protections Afforded by Americans With Disabilities Act